Location of Repository

Investigation of cardiac myosin binding protein C (cMyBPC) domains and their interactions

By Joyce Ratti


Myosin binding protein C (MyBPC) is a multidomain protein present in the thick\ud filament of striated muscles involved in both sarcomere formation and contraction. It\ud appears that the C-terminus of the protein is involved in sarcomere formation, through\ud interaction with Light Meromyosin (LMM), while the N-terminus seems to play a role\ud in muscle contraction, being localized close to the motor domain of myosin that\ud interacts with the thin filament protein actin, causing muscles to contract. It exists in\ud three different isoforms, one for each type of muscle, the cardiac isoform being linked\ud to hypertrophic cardiomyopathy (HCM), a genetic disorder associated with cardiac\ud dysfunction that can manifest itself through arrhythmias, heart failure and sudden\ud cardiac death, especially in the young. The present work has focused on two aspects of\ud the cardiac isoform (cMyBPC) investigating both the function and the role in sarcomere\ud assembly played by cMyBPC. The first part of the research presented in this thesis\ud consisted in the determination of the three dimensional structure of the cardiac specific\ud N-terminal domain cC0 using NMR spectroscopy, and the investigation of the\ud interaction with its probable binding partner, the regulatory light chain of myosin,\ud through ^1H/^{15}N HSQC NMR spectroscopy titrations. The knowledge of the three\ud dimensional structure has proven a vital tool to map the interacting surface on cC0,\ud giving the possibility to make hypothesis on the way cMyBPC might interact with the\ud S1 domain of myosin, thus influencing muscle contraction. The second part of this\ud research is based on the hypothesis that the central domain cC5 could interact with\ud domain cC8 of another molecule of the same protein, suggesting that the way cMyBPC\ud could incorporate in the sarcomere would be through a trimeric collar wrapped around\ud the myosin filament. This aspect has being studied using ^1H/^{15}N HSQC NMR\ud spectroscopy titrations but no conclusive results were obtained, suggesting that this\ud interaction might not take place and indicating an axial arrangement, with cMyBPC\ud running parallel to the thick filament, as the most likely

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/7857

Suggested articles



  1. (1992). 1H, 13C, and 15N NMR backbone assignments and secondary structure of human interferon-gamma.
  2. (2005). A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet.
  3. (1990). A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.
  4. (1996). A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy.
  5. (1996). A mouse model of familial hypertrophic cardiomyopathy.
  6. (1998). A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy.
  7. (1973). A new protein of the thick filaments of vertebrate skeletal myofibrils. Extractions, purification and characterization.
  8. (1990). A novel approach for sequential assignment of 1H, 13C, and 15N spectra of proteins: heteronuclear triple-resonance threedimensional NMR spectroscopy. Application to calmodulin.
  9. (1993). A survey of interactions made by the giant protein titin.
  10. (1993). A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm.
  11. (1999). A transgenic rabbit model for human hypertrophic cardiomyopathy.
  12. (1998). A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy.
  13. (1995). Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy.
  14. (2000). Abnormalities of calcium cycling in the hypertrophied and failing heart.
  15. Activation of myocardial contraction by the N-terminal domains of myosin binding protein-C. Circ Res.
  16. (1996). Alteration of myosin cross bridges by phosphorylation of myosin-binding protein C in cardiac muscle.
  17. (2001). Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.
  18. (1993). Amino acid type determination in the sequential assignment procedure of uniformly 13C/15N-enriched proteins.
  19. (1996). AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR.
  20. (1988). Architecture of the sarcomere matrix of skeletal muscle: immunoelectron microscopic evidence that suggests a set of parallel inextensible nebulin filaments anchored at the Z line.
  21. (1997). Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution.
  22. (2003). Automated NMR protein structure calculation. Progress in nuclear magnetic resonance spectroscopy.
  23. (1989). b. 3-Dimensional heteronuclear NMR of N-15 labeled proteins.
  24. (1992). Backbone dynamics of calmodulin studied by 15N relaxation using inverse detected two-dimensional NMR spectroscopy: the central helix is flexible.
  25. (2004). Bacteria co-transformed with recombinant proteins and chaperones cloned in independent plasmids are suitable for expression tuning.
  26. (1999). cAPK-phosphorylation controls the interaction of the regulatory domain of cardiac myosin binding protein C with myosin-S2 in an on-off fashion.
  27. (2004). Cardiac myosin binding protein C: its role in physiology and disease. Circ Res.
  28. (1999). Cardiac myosin binding protein C. Circ Res.
  29. (1995). Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy.
  30. (2005). Cardiac myosinbinding protein-C phosphorylation and cardiac function. Circ Res.
  31. (2001). Changes in cardiac contractility related to calcium-mediated changes in phosphorylation of myosinbinding protein C.
  32. (1954). Changes in the cross-striations of muscle during contraction and stretch and their structural interpretation.
  33. (1992). Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy.
  34. (1998). Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene.
  35. (1999). Comparative aspects of muscle elastic proteins. Rev Physiol Biochem Pharmacol.
  36. (2001). Conformational properties of alpha-synuclein in its free and lipid-associated states.
  37. (1999). COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes.
  38. (1999). Crystal structure of a heparin- and integrin-binding segment of human fibronectin.
  39. (1999). Crystal structure of a tandem pair of fibronectin type III domains from the cytoplasmic tail of integrin alpha6beta4.
  40. (1998). Crystal structure of a vertebrate smooth muscle myosin motor domain and its complex with the essential light chain: visualization of the pre-power stroke state.
  41. (2008). Crystal structure of the C1 domain of cardiac myosin binding protein-C: implications for hypertrophic cardiomyopathy.
  42. (2000). DaliLite workbench for protein structure comparison.
  43. (1987). Dephosphorylation of cardiac myofibril C-protein by protein phosphatase 1 and protein phosphatase 2A. Biochim Biophys Acta.
  44. (2001). Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations.
  45. (1990). Deviation from the single two- parameter model-free approach to the interpretation of nitrogen-15 nuclear magnetic relaxation of proteins.
  46. (1990). Differential distribution of subset of myofibrillar proteins in cardiac, nonstrated and strated myofibrils.
  47. (1999). Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice.
  48. (2007). Dissecting the N-terminal myosin binding site of human cardiac myosin-binding protein C. Structure and myosin binding of domain C2.
  49. (1989). Does titin regulate the length of muscle thick filaments?
  50. (1988). Domains, motions and regulation in the myosin head.
  51. (1987). Dynamics of Proteins and Nuclei Acids.
  52. (2003). Effect of MyBP-C binding to actin on contractility in heart muscle.
  53. (1979). Effects of C-protein on syntetic myosin filament structure.
  54. (1979). Effects of C-protein on synthetic myosin filament structure.
  55. (1982). Effects of cholinergic and adrenergic agonists on phosphorylation of a 165,000-dalton myofibrillar protein in intact cardiac muscle.
  56. (2006). Effects of the N-terminal domains of myosin binding protein-C in an in vitro motility assay: Evidence for long-lived cross-bridges.
  57. (1963). Electron Microscope Studies On The Structure Of Natural And Synthetic Protein Filaments From Striated Muscle.
  58. (1986). Electron microscopy of C-protein molecules from chicken skeletal muscle.
  59. (1987). Electron microscopy of cardiac myosin: its shape and properties as determined by the regulatory light chain.
  60. (1994). Engineering proteins to facilitate bioprocessing. Trends Biotechnol.
  61. (1999). Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci.
  62. (1990). Evolution of EF-hand calcium-modulated proteins. I. Relationships based on amino acid sequences.
  63. (2000). Expression of soluble heterologous proteins via fusion with NusA protein. inNovation (newsletter of Novagen).
  64. (1999). Expression of the Methanobacterium thermoautotrophicum hpt gene, encoding hypoxanthine (Guanine) phosphoribosyltransferase, in Escherichia coli.
  65. (2001). Familial hypertrophic cardiomyopathy mutations in the regulatory light chains of myosin affect their structure, Ca2+ binding, and phosphorylation.
  66. (1998). Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res.
  67. (1993). Filamentous aggregates of native titin and binding of C-protein and AMP-deaminase. Arch Biochem Biophys.
  68. (1990). H-1-H1 correlation via isotopic mixing of C-13 magnetization, a new 3-dimensional approch for assigning H-1 and C13 spectra of C-13 enriched proteins.
  69. (1997). High-level expression of soluble protein in Escherichia coli using a His6-tag and maltose-binding-protein double-affinity fusion system. Protein Expr Purif.
  70. (1993). HNCACB, a high-sensitivity 3D NMR experiment to correlate amide- proton and nitrogen resonances with the alpha- carbon and beta- carbon resonances in proteins.
  71. (2001). Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C.
  72. (2003). Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.
  73. (2002). Hypertrophic cardiomyopathy in cardiac myosin binding protein-C knockout mice. Circ Res.
  74. (2002). Hypertrophic cardiomyopathy: a systematic review.
  75. (2003). Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy.
  76. (2003). Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy." Circulation.
  77. (2003). Hypertrophic cardiomyopathy: two homozygous cases with "typical" hypertrophic cardiomyopathy and three new mutations in cases with progression to dilated cardiomyopathy.
  78. (1998). Identification of a new missense mutation in MyBP-C associated with hypertrophic cardiomyopathy.
  79. (2002). Identification of novel interactions between domains of Myosin binding protein-C that are modulated by hypertrophic cardiomyopathy missense mutations. Circ Res.
  80. (1999). Identification of the A-band localization domain of myosin binding proteins C and H (MyBP-C, MyBP-H) in skeletal muscle.
  81. (2003). Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden.
  82. (1996). Immunoglobulin-like modules from titin I-band: extensible components of muscle elasticity.
  83. (1999). In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. Circ Res.
  84. (2003). Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res.
  85. (1975). Interaction of C-protein with myosin, myosin rod and light meromyosin.
  86. (1988). Interaction of C-protein with pH 8.0 synthetic thick filaments prepared from the myosin of vertebrate skeletal muscle.
  87. (1999). Introduction to Protein Structure.
  88. (1997). Isoformspecific interaction of the myosin-binding proteins (MyBPs) with skeletal and cardiac myosin is a property of the C-terminal immunoglobulin domain.
  89. (1974). Light and x-ray diffraction studies on chick skeletal muscle under controlled physiological conditions.
  90. (1992). Mammalian skeletal muscle Cprotein: purification from bovine muscle, binding to titin and the characterization of a full-length human cDNA.
  91. (1994). Many of the immunoglobulin superfamily domains in cell adhesion molecules and surface receptors belong to a new structural set which is close to that containing variable domains.
  92. (1982). Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity.
  93. (1982). Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 2. Analysis of experimental results.
  94. (1998). Molecular pathology of familial hypertrophic cardiomyopathy caused by mutations in the cardiac myosin binding protein C gene.
  95. (2004). Morphological and functional alterations in ventricular myocytes from male transgenic mice with hypertrophic cardiomyopathy. Circ Res.
  96. Multiple structures of thick filaments in resting cardiac muscle and their influence on cross-bridge interactions.
  97. (1999). Muscle assembly: a titanic achievement? Curr Opin Cell Biol.
  98. (1999). Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C.
  99. (1995). Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy.
  100. (2002). Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
  101. (1998). Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.
  102. (1995). Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy.
  103. (2004). Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
  104. (2008). Myosin binding protein C positioned to play a key role in regulation of muscle contraction: structure and interactions of domain C1.
  105. (2000). Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2. Circ Res.
  106. (2000). Myosin binding protein C, a potential regulator of cardiac contractility. Circ Res.
  107. (1998). Myosin rod-packing schemes in vertebrate muscle thick filaments.
  108. (2005). Myosin-binding protein C phosphorylation, myofibril structure, and contractile function during low-flow ischemia.
  109. (1980). Natural abundance N-15 NMR by enhanced heteronuclear spectroscopy.
  110. (1996). Nebulin and nebulin-related proteins in striated muscle. Adv Biophys.
  111. (2000). Novel cardiac beta-myosin heavy chain gene missense mutations (R869C and R870C) that cause familial hypertrophic cardiomyopathy. Hum Mutat.
  112. (2002). Novel mutations in sarcomeric protein genes in dilated cardiomyopathy.
  113. (1997). Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein.
  114. (1997). Objectively judging the quality of a protein structure from a Ramachandran plot.
  115. (1996). Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels.
  116. (1982). Periodic charge distributions in the myosin rod amino acid sequence match cross-bridge spacings in muscle.
  117. (1988). Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts.
  118. (1991). Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II.
  119. (1995). Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction?
  120. (1997). Probing molecular motion by NMR.
  121. (1989). Production of soluble protein in bacteria.
  122. (1999). Protein backbone angle restraints from searching a database for chemical shift and sequence homology.
  123. (1996). Protein dynamics and conformational transitions in allosteric proteins. Prog Biophys Mol Biol.
  124. (1989). Protein folding intermediates and inclusion body formation.
  125. (2002). Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA.
  126. (1988). Proteins: a Theoretical Prospective of Dynamics, Structure and Thermodinamics.
  127. (1981). Proteolytic approach to structure and function of actin recognition site in myosin heads.
  128. (1957). Quantitative studies on the structure of crossstriated myofibrils. I. Investigations by interference microscopy.
  129. (1957). Quantitative studies on the structure of crossstriated myofibrils. II. Investigations by biochemical techniques.
  130. (2000). Regulation of contraction in striated muscle. Physiol Rev.
  131. (1998). Relation between crossbridge structure and actomyosin ATPase activity in rat heart. Circ Res.
  132. (1989). Repetitive titin epitopes with a 42 nm spacing coincide in relative position with known A band striations also identified by major myosin-associated proteins. An immunoelectronmicroscopical study on myofibrils.
  133. (2002). Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly.
  134. (1995). Secondary structure determination by NMR spectroscopy of an immunoglobulin-like domain from the giant muscle protein titin.
  135. (1986). Site-directed mutagenesis of the regulatory light-chain Ca2+/Mg2+ binding site and its role in hybrid myosins.
  136. (2008). Small-angle X-ray scattering reveals the N-terminal domain organization of cardiac myosin binding protein C.
  137. (2002). STARS, a striated muscle activator of Rho signaling and serum response factor-dependent transcription.
  138. (1963). Stereochemistry of polypeptide chain configurations.
  139. (1996). Strategies for achieving high-level expression of genes in Escherichia coli.
  140. (1998). Structural and functional responses of mammalian thick filaments to alterations in myosin regulatory light chains.
  141. (1987). Structural aspects of troponin-tropomyosin regulation of skeletal muscle contraction. Annu Rev Biophys Biophys Chem.
  142. (1954). Structural changes in muscle during contraction; interference microscopy of living muscle fibres.
  143. (2001). Structural evidence for a possible role of reversible disulphide bridge formation in the elasticity of the muscle protein titin.
  144. (2003). Structural evidence for the interaction of C-protein (MyBP-C) with actin and sequence identification of a possible actinbinding domain.
  145. (1992). Structure and function of actin.
  146. (1985). Structure of C protein purified from cardiac muscle.
  147. (2003). Structure, stability and dynamics of the central domain of cardiac myosin binding protein C (MyBP-C): implications for multidomain assembly and causes for cardiomyopathy.
  148. (1993). Study of protein dynamics by NMR.
  149. (1969). Substructure of the myosin molecule. I. Subfragments of myosin by enzymic degradation.
  150. (2008). Support for a trimeric collar of myosin binding protein C in cardiac and fast skeletal muscle, but not in slow skeletal muscle.
  151. (2005). Textbook of Medical Physiology.
  152. (1978). The beta bulge: a common small unit of nonrepetitive protein structure.
  153. (1978). The binding of skeletal muscle C-protein to F-actin, and its relation to the interaction of actin with myosin subfragment-1.
  154. (1986). The binding of skeletal muscle C-protein to regulated actin.
  155. (1999). The C-protein (myosin binding protein C) family: regulators of contraction and sarcomere formation? Rev Physiol Biochem Pharmacol.
  156. (1983). The C-proteins of rabbit red, white, and cardiac muscles.
  157. (2002). The C-terminal IgI domains of myosinbinding proteins C and H (MyBP-C and MyBP-H) are both necessary and sufficient for the intracellular crosslinking of sarcomeric myosin in transfected non-muscle cells.
  158. (1996). The carboxyl terminus of myosin binding protein C (MyBP-C, C-protein) specifies incorporation into the A-band of striated muscle.
  159. (1997). The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res.
  160. (1957). The double array of filaments in cross-striated muscle.
  161. (2001). The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.
  162. (1997). The giant protein titin. Emerging roles in physiology and pathophysiology. Circ Res.
  163. (1978). The interaction of C-protein with heavy meromyosin and subfragment-2.
  164. (1999). The interface between MyBP-C and myosin: site-directed mutagenesis of the CX myosin-binding domain of MyBP-C.
  165. (1979). The limited tryptic cleavage of chymotryptic S-1: an approach to the characterization of the actin site in myosin heads.
  166. (1967). The low-angle x-ray diagram of vertebrate striated muscle and its behaviour during contraction and rigor.
  167. (1993). The major myosin-binding domain of skeletal muscle MyBP-C (C protein) resides in the COOH-terminal, immunoglobulin C2 motif.
  168. (1997). The management of hypertrophic cardiomyopathy.
  169. (1969). The mechanism of muscular contraction.
  170. (1998). The NH2 terminus of titin spans the Z-disc: its interaction with a novel 19-kD ligand (T-cap) is required for sarcomeric integrity.
  171. (1999). The physiological role of titin in striated muscle. Rev Physiol Biochem Pharmacol.
  172. (1994). The premyofibil: evidence for its role in myofibrillogenesis.
  173. (1997). The role of the proline-rich region in A1-type myosin essential light chains: implications for information transmission in the actomyosin complex.
  174. (1997). The role of the thioredoxin and glutaredoxin pathways in reducing protein disulfide bonds in the Escherichia coli cytoplasm.
  175. (2004). The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochem Biophys Res Commun.
  176. (2006). The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling.
  177. (1998). The three-dimensional structure of a type I module from titin: a prototype of intracellular fibronectin type III domains.
  178. (1992). The threedimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions.
  179. (1994). The tyrosine corner: a feature of most Greek key beta-barrel proteins. Protein Sci.
  180. (2000). Thioredoxin as a fusion partner for soluble recombinant protein production in Escherichia coli. Methods Enzymology.
  181. (1993). Threedimensional structure of myosin subfragment-1: a molecular motor.
  182. (1996). Titin as a scaffold and spring.
  183. (1995). Titins: giant proteins in charge of muscle ultrastructure and elasticity.
  184. (1997). Torsion angle dynamics for NMR structure calculation with the new program DYANA.
  185. (1992). Towards a molecular understanding of titin.
  186. (1996). Triggers for sudden cardiac death in the athlete. Cardiol Clin.
  187. (1998). Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res.
  188. (1998). Troponin T: genetics, properties and function.
  189. (2006). Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene.
  190. (2001). Vertebrate tropomyosin: distribution, properties and function.
  191. (1996). World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.
  192. (1974). X-ray diffraction patterns from mammalian heart muscle.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.